Canji Jeter Pharmaceutical-B (09966): The latest research findings of JSKN016 will be presented at the 2026 ASCO Annual Meeting.

Finance APP News: Kangning Jerry Pharmaceutical-B (09966) announced that the latest research results of the Phase I clinical study (Study Number: JSKN016-101) of JSKN016 (an ADC targeting TROP2 and HER3) for the treatment of HER2-positive locally advanced or metastatic breast cancer have been presented during the poster display session at the 2026 ASCO Annual Meeting held from May 29th to June 2nd, 2026.